Fundraising Fox

Vergentbio

Minneapolis, US · 3 known investors

Find your way into Vergentbio

Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.

BiotechDeep TechHealthtechMedical Devices

Founders & leadership

JY
Jeffrey YureckoExecutive
JSJohn Santini
John SantiniExecutive
JSJohn Santini, PhD
John Santini, PhDPresident and Chief Executive Officer

Board

JJ
Jeff JulkowskiBoard director
RW
Raymond WongBoard director
AWAnita Watkins
Anita WatkinsinBoard DirectorManaging Director at Rex Health Ventures
SD
Samuel Dean BanksBoard director
RE
Ryan EgelandBoard director
BH
Bobby HelmedagBoard director
DK
Douglas KohrsBoard director

Investors · 3

Colle Capital PartnersNew York · $500K – $2M
Windham Capital PartnersNew York · $1M – $5M
Spring Mountain CapitalreportedNew York

Reported raises · per SEC filings

Form D private placements

$57M disclosed across 5 of 6 rounds · 2018–2025

▶$18.7MraisedOct 2025 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Bobby HelmedagDirector
  • Jeffrey YureckoExecutive Officer
  • Anita WatkinsDirector
  • John T. Santini, Jr.Executive Officer, Director
  • Raymond WongDirector
  • Douglas KohrsDirector
Offering amount
$32M
Amount sold
$18.7M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.8MraisedFeb 2025 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeff JulkowskiDirector
  • Douglas KohrsDirector
  • Raymond WongDirector
  • Jeffrey YureckoExecutive Officer
  • John SantiniExecutive Officer, Director
  • Anita WatkinsDirector
  • Samuel Dean BanksDirector
  • Ryan EgelandDirector
  • Bobby HelmedagDirector
Offering amount
$5M
Amount sold
$3.8M
First sale
Feb 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$21.5MraisedOct 2022 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ryan EgelandDirector
  • John SantiniExecutive Officer, Director
  • Margo ShoupDirector
  • Douglas KohrsDirector
  • Jeffrey YureckoExecutive Officer
  • Raymond WongDirector
  • Jeffrey JulkowskiDirector, Promoter
  • Samuel BanksDirector
Offering amount
$22.1M
Amount sold
$21.5M
First sale
Aug 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.2MraisedNov 2021 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jeffrey JulkowskiDirector, Promoter
  • Raymond WongDirector
  • John SantiniExecutive Officer, Director
  • Ryan EgelandDirector
  • Samuel Dean BanksDirector
  • Douglas KohrsDirector
  • Jeffrey YureckoExecutive Officer
Offering amount
$2M
Amount sold
$1.2M
First sale
Nov 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$11.9MraisedSep 2020 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel Dean BanksDirector
  • Douglas KohrsDirector
  • Ryan EgelandDirector
  • John SantiniExecutive Officer, Director
  • Jeffrey JulkowskiDirector, Promoter
  • Jeffrey YureckoExecutive Officer
  • Raymond WongDirector
Offering amount
$11.9M
Amount sold
$11.9M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Vergent Bioscience, Inc. has filed a notice of an exempt offering of securities to raise $31,957,273.00 in New Funding. - intelligence360intelligence360.news · Nov 2025Vergent Bioscience raises $21.5 million, reflecting sustained investor interest in life sciencesstartribune.com · Oct 2022Tumor-Spotting Startup Vergent Bioscience Lands $21.5M | Twin Cities Businesstcbmag.com · Oct 2022Vergent Bioscience raises $21.5M in Series B funding - Minneapolis / St. Paul Business Journalbizjournals.com · Oct 2022Stealthy Vergent Bioscience raises $9m for tumor-fluorescing tech - MassDevicemassdevice.com · Jun 2018Vergent Bioscience Raises $8.7 Million in Series A Financing Led by Spring Mountain Capitalprnewswire.com · Jun 2018

Frequently asked questions

What does Vergentbio do?
Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.
Who are Vergentbio's investors?
Vergentbio's investors include Colle Capital Partners, Windham Capital Partners, Spring Mountain Capital.
How much funding has Vergentbio raised?
Vergentbio has disclosed $57M raised across 5 of its 6 known rounds.
Where is Vergentbio headquartered?
Vergentbio is headquartered in Minneapolis, US.